Blood cancer Clinical Trials in Philadelphia, PA

As of June 2026, 87 paid clinical trials are recruiting for Blood cancer in Philadelphia, Pennsylvania. Blood cancer trials investigate CAR-T cell therapies, bispecific antibodies, BTK and BCL-2 inhibitors, and novel combinations across leukemias, lymphomas, myeloma, and myelodysplastic syndromes. Compensation typically covers time, travel, and study visits, and many studies also include study-related medical care at no cost.

Recruiting trial data synced daily from ClinicalTrials.gov. Last sync: June 12, 2026.

Filter results

Filter results

State

City

Facility

Phase

Study type

Intervention

Recruitment status

Condition

Sex

Age

Healthy volunteers only

87 clinical trials for Blood cancer

·Clear filters·↓ Download CSV

Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma

for Multiple Myeloma

41 locations incl. Birmingham

Sponsor: Juno Therapeutics, Inc., a Bristol-Myers Squibb Company

Sex: All·Age: 18+

Code: NCT06297226·Phase 2·Recruiting

Apply to this trial

SNDX-5613 and Gilteritinib for the Treatment of Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia and Concurrent MLL-Rearrangement or NPM1 Mutation

for Acute Myeloid Leukemia With FLT3/ITD Mutation

4 locations incl. Chapel Hill

Sponsor: Uma Borate

Sex: All·Age: 18+

Code: NCT06222580·Phase 1·Recruiting

Apply to this trial

Hypertension and Arrhythmias in CLL Patients Treated With BTK Inhibitors

for Chronic Lymphocytic Leukemia

1 location in Philadelphia

Sponsor: Abramson Cancer Center at Penn Medicine

Sex: All·Age: 22+

Code: NCT06211413·Enrolling By Invitation

AZD3470 as Monotherapy or in Combination With Anticancer Agent(s) in Participants With Haematologic Malignancies.

for Lymphoma

7 locations incl. Duarte

Sponsor: AstraZeneca

Sex: All·Age: 12+

Code: NCT06137144·Phase 1, Phase 2·Recruiting

Apply to this trial

A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortezomib, and Dexamethasone in Participants With Relapsed or Refractory Myeloma Who Have Received an Anti-CD38 Antibody and Lenalidomide

for Multiple Myeloma

Drug: Talquetamab

49 locations incl. Clovis

Sponsor: Janssen Research & Development, LLC

Sex: All·Age: 18+

Code: NCT06208150·Phase 3·Recruiting

Apply to this trial

AZD0305 as Monotherapy or in Combination With Anticancer Agents in Participants With Multiple Myeloma

for Multiple Myeloma

9 locations incl. Duarte

Sponsor: AstraZeneca

Sex: All·Age: 18+

Code: NCT06106945·Phase 1, Phase 2·Recruiting

Apply to this trial

A Long-term Follow-up Study of Subjects Who Received CRISPR CAR T Cellular Therapies

for Hematologic Malignancy

17 locations incl. Duarte

Sponsor: CRISPR Therapeutics AG

Sex: All·Age: 18+

Code: NCT06208878·Enrolling By Invitation

Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution

for Hematologic Malignancy

Drug: Venetoclax

5 locations incl. Aurora

Sponsor: Children's Hospital Medical Center, Cincinnati

Sex: All·Age: 0 - 38

Code: NCT06131801·Recruiting

Apply to this trial

TmCD19-IL18 in CD19+ Cancers

for Non Hodgkin Lymphoma

1 location in Philadelphia

Sponsor: University of Pennsylvania

Sex: All·Age: 18+

Code: NCT05989204·Phase 1·Recruiting

Apply to this trial

Tazemetostat and Palbociclib With CPX-351for R/R AML

for Recurrent Acute Myeloid Leukemia

1 location in Philadelphia

Sponsor: Thomas Jefferson University

Sex: All·Age: 18+

Code: NCT05627232·Phase 1·Recruiting

Apply to this trial

A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML

for Acute Myeloid Leukemia

Drug: Venetoclax

44 locations incl. Phoenix

Sponsor: Kura Oncology, Inc.

Sex: All·Age: 18+

Code: NCT05735184·Phase 1·Recruiting

Apply to this trial

A Study to Compare Iberdomide Maintenance Versus Lenalidomide Maintenance Therapy Following Autologous Stem Cell Transplant in Participants With Newly Diagnosed Multiple Myeloma

for Multiple Myeloma

Drug: Iberdomide

44 locations incl. Aurora

Sponsor: Bristol-Myers Squibb

Sex: All·Age: 18+

Code: NCT05827016·Phase 3·Recruiting

Apply to this trial

Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma

for Diffuse Large B-Cell Lymphoma

87 locations incl. Tucson

Sponsor: SWOG Cancer Research Network

Sex: All·Age: 18+

Code: NCT05633615·Phase 2·Recruiting

Apply to this trial

Study of Rondecabtagene Autoleucel in Aggressive Large B-Cell Lymphoma

for Relapsed Non-Hodgkin Lymphoma

32 locations incl. Irvine

Sponsor: Lyell Immunopharma, Inc.

Sex: All·Age: 18+

Code: NCT05826535·Phase 1, Phase 2·Recruiting

Apply to this trial

Exercise Training and NR Supplementation Trial to Improve Fitness in AYA HCT Survivors

for Lymphoblastic Leukemia

3 locations incl. Duarte

Sponsor: Children's Hospital of Philadelphia

Sex: All·Age: 10 - 30

Code: NCT05194397·Phase 2·Recruiting

Apply to this trial

A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma

for Multiple Myeloma

13 locations incl. San Francisco

Sponsor: K36 Therapeutics, Inc.

Sex: All·Age: 18+

Code: NCT05651932·Phase 1·Recruiting

Apply to this trial

Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies

for Hematologic Malignancy

29 locations incl. Los Angeles

Sponsor: Therapeutic Advances in Childhood Leukemia Consortium

Sex: All·Age: 1 - 21

Code: NCT05476770·Phase 1·Recruiting

Apply to this trial

A Study of TSC-100 and TSC-101 in AML, ALL and MDS in Patients Undergoing Allogeneic Peripheral Blood Stem Transplantation

for AML

15 locations incl. Duarte

Sponsor: TScan Therapeutics, Inc.

Sex: All·Age: 18+

Code: NCT05473910·Phase 1·Recruiting

Apply to this trial

Venetoclax in Children With Relapsed Acute Myeloid Leukemia (AML)

for Acute Myeloid Leukemia

Drug: Venetoclax

45 locations incl. Phoenix

Sponsor: PedAL BCU, LLC

Sex: All·Age: 29 Days - 21

Code: NCT05183035·Phase 3·Recruiting

Apply to this trial

Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation

for Multiple Myeloma

Drug: Teclistamab

42 locations incl. Phoenix

Sponsor: European Myeloma Network B.V.

Sex: All·Age: 18+

Code: NCT05243797·Phase 3·Recruiting

Apply to this trial

Study of Tagraxofusp for Post-Transplant Maintenance for Patients With CD 123+ AML, MDS, MF and CMML (HSCT 002)

for Myelofibrosis

2 locations incl. Philadelphia

Sponsor: Karen Ballen, MD

Sex: All·Age: 18 - 75

Code: NCT05233618·Phase 1·Recruiting

Apply to this trial

A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma

for Non-Hodgkin Lymphoma

Drug: Epcoritamab

18 locations incl. Tucson

Sponsor: Genmab

Sex: All·Age: 18+

Code: NCT05283720·Phase 2·Recruiting

Apply to this trial

Study of DISC-0974 (RALLY-MF) in Participants With Myelofibrosis or Myelodysplastic Syndrome and Anemia

for Myelofibrosis

22 locations incl. Duarte

Sponsor: Disc Medicine, Inc

Sex: All·Age: 18+

Code: NCT05320198·Phase 1, Phase 2·Recruiting

Apply to this trial

The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study

for Acute Lymphoblastic Leukemia

164 locations incl. Birmingham

Sponsor: PedAL BCU, LLC

Sex: All·Age: Up to 22

Code: NCT04726241·Phase 1, Phase 2·Recruiting

Apply to this trial

Long-Term Follow-up Study

for Lymphoma, Non-Hodgkin

31 locations incl. Birmingham

Sponsor: Caribou Biosciences, Inc.

Sex: All·Age: 18+

Code: NCT05332054·Enrolling By Invitation

A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel

for Multiple Myeloma

28 locations incl. Phoenix

Sponsor: Janssen Research & Development, LLC

Sex: All·Age: 18+

Code: NCT05201781·Phase 4·Recruiting

Apply to this trial

A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)

for Leukemia, Myeloid, Acute

33 locations incl. Newport Beach

Sponsor: Sumitomo Pharma America, Inc.

Sex: All·Age: 12+

Code: NCT04988555·Phase 1, Phase 2·Recruiting

Apply to this trial

A Phase I Safety and Pharmacokinetic Study of Gamitrinib Administered Intravenously to Patients With Advanced Cancer

for Lymphoma

1 location in Philadelphia

Sponsor: Fox Chase Cancer Center

Sex: All·Age: 18+

Code: NCT04827810·Phase 1·Recruiting

Apply to this trial

CAR-T Followed by Bispecific Antibodies

for Large B-cell Lymphoma

2 locations incl. Omaha

Sponsor: Abramson Cancer Center at Penn Medicine

Sex: All·Age: 18+

Code: NCT04889716·Phase 2·Recruiting

Apply to this trial

A Phase 1/2 Study of Bleximenib in Participants With Acute Leukemia (cAMeLot-1)

for Acute Leukemia

26 locations incl. Duarte

Sponsor: Janssen Research & Development, LLC

Sex: All·Age: 2+

Code: NCT04811560·Phase 1, Phase 2·Recruiting

Apply to this trial

Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study

for Chronic Lymphocytic Leukemia

621 locations incl. Birmingham

Sponsor: National Cancer Institute (NCI)

Sex: All·Age: 18+

Code: NCT04269902·Phase 3·Recruiting

Apply to this trial

A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations

for Acute Myeloid Leukemia

185 locations incl. Birmingham

Sponsor: Children's Oncology Group

Sex: All·Age: Up to 21

Code: NCT04293562·Phase 3·Recruiting

Apply to this trial

A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations

for Locally Advanced Solid Tumors

Drug: Repotrectinib

20 locations incl. Los Angeles

Sponsor: Turning Point Therapeutics, Inc.

Sex: All·Age: Up to 25

Code: NCT04094610·Phase 1, Phase 2·Recruiting

Apply to this trial

A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation

for Acute Myeloid Leukemia

Drug: Revumenib

22 locations incl. Duarte

Sponsor: Syndax Pharmaceuticals

Sex: All·Age: 30 Days+

Code: NCT04065399·Phase 1, Phase 2·Recruiting

Apply to this trial

Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy

for B Acute Lymphoblastic Leukemia

203 locations incl. Birmingham

Sponsor: Children's Oncology Group

Sex: All·Age: 365 Days - 25

Code: NCT03959085·Phase 3·Recruiting

Apply to this trial

A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas

for Advanced Solid Tumor

Drug: Tulmimetostat

17 locations incl. Atlanta

Sponsor: Novartis Pharmaceuticals

Sex: All·Age: 18+

Code: NCT04104776·Phase 1, Phase 2·Recruiting

Apply to this trial

Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies

for Haematological Malignancy

6 locations incl. Atlanta

Sponsor: CellCentric Ltd.

Sex: All·Age: 18+

Code: NCT04068597·Phase 1, Phase 2·Recruiting

Apply to this trial

Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO

for Autoimmune Disease

Drug: Nivolumab

51 locations incl. Birmingham

Sponsor: National Cancer Institute (NCI)

Sex: All·Age: 18+

Code: NCT03816345·Phase 1·Recruiting

Apply to this trial

CD45RA Depleted Peripheral Stem Cell Addback for Viral or Fungal Infections Post TCRαβ/CD19 Depleted HSCT

for Acute Leukemia

1 location in Philadelphia

Sponsor: Children's Hospital of Philadelphia

Sex: All·Age: Up to 25

Code: NCT03810196·Recruiting

Apply to this trial

Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587)

for Solid Tumors

65 locations incl. Tucson

Sponsor: Merck Sharp & Dohme LLC

Sex: All·Age: 18+

Code: NCT03486873·Phase 3·Recruiting

Apply to this trial

Conditions in Blood cancer (Philadelphia, PA)

Acute myeloid leukemia (AML)· 24 Non-Hodgkin lymphoma· 20 Diffuse large B-cell lymphoma (DLBCL)· 14 Multiple myeloma· 13 Hematologic malignancy· 13 Leukemia (other)· 11 Myelodysplastic syndromes (MDS)· 11 Chronic lymphocytic leukemia (CLL)· 7 Hodgkin lymphoma· 6 Small lymphocytic lymphoma· 5 Acute lymphoblastic leukemia· 4 Myelofibrosis· 4 Follicular lymphoma· 4 Myeloproliferative neoplasm· 3 Mantle cell lymphoma· 3 Burkitt lymphoma· 3 Chronic myelomonocytic leukemia· 2 Marginal zone lymphoma· 2